These changes do not liberate medicinal cannabis users; instead, they establish a digital surveillance framework that explicitly targets and bans people with chronic illnesses from driving.
A major Lancet Psychiatry meta-analysis on cannabinoids and mental health was reported accurately on some points, incompletely on others, and misleadingly on at least one finding that cuts against a well-established media narrative. Often, all three occurred in the same article.`
"Australia cannot refinery-build its way out of this crisis quickly enough. But it can grow its way toward a more resilient position — if it chooses to."
The endocannabinoid system plays a modulatory role in both pain processing and neurological function. It is altered in both Alzheimer's disease and chronic pain states, making it an area of active research interest.
For a veteran in outback Queensland newly diagnosed with a terminal illness, "find a specialist and attend in person first" is not a neutral administrative requirement. It is a genuine barrier to care, arriving at the worst possible time.
The study was supported by philanthropic funding to the HealthPartners Cancer Research Centre, with cannabis products provided by Vireo Health (GreenGoods, Minnesota).
Recruitment of adults with medicinal cannabis prescriptions has now concluded.
Schedule III classification would recognise cannabis as having accepted medical use and lower abuse potential than Schedule I or II substances.
The 22% reduction in opioid use may seem modest, but researchers emphasise this aligns with current clinical recommendations for gradual opioid tapering over extended periods rather than rapid cessation.
The most alarming finding from the trials is the catastrophic variability in imported seed quality.
The implications for Australia's emerging cannabis industry are substantial.
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.